Carlsbad, CA — October 2, 2025 — Leads & Copy —Palisade Bio, Inc. (Nasdaq: PALI) closed its previously announced underwritten public offering of approximately $138 million in gross proceeds to support the upcoming Phase 2 clinical development program for PALI-2108 in Ulcerative Colitis.
The offering included the full exercise of the underwriter’s over-allotment option to purchase additional shares of common stock. B Group Capital and Columbia Threadneedle Investments led the offering, with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands Capital, Deep Track Capital, Janus Henderson Investors, Octagon Capital, Perceptive Advisors, RA Capital Management, Squadron Capital Management, and a large healthcare dedicated mutual fund.
According to J.D. Finley, CEO of Palisade Bio, the funding validates the strength of the company’s lead program and allows it to execute a more robust development plan. The offering comprised 197,154,844 shares of its common stock (or common stock equivalents) at a public offering price of $0.70 per share (or $0.6999 per common stock equivalent).
Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering, which was made pursuant to a registration statement on Form S-1 (File No. 333-290568) and an additional registration statement on Form S-1MEF (File No. 333-290644).
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
Source: Palisade Bio
